Glomerular nephropathy therapeutic - Everest Medicines
Latest Information Update: 22 Aug 2023
At a glance
- Originator Everest Medicines
- Class Anti-inflammatories; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glomerulonephritis
Most Recent Events
- 22 Aug 2023 Preclinical trials in Glomerulonephritis in China (unspecified route) (Everest Medicines pipeline, August 2023)
- 15 Nov 2022 Early research in Glomerulonephritis in China (unspecified route)
- 14 Nov 2022 Everest Medicines plans for an IND application for Glomerulonephritis till the year 2024